CLN-049
Asset
T cell engager targeting FLT3
- Stage
- Phase 2
- Modality
- Antibody
- Target
- FLT3
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Relapsed/refractory acute myeloid leukemia
Phase 2, globenewswire.com, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
Every asset’s record: target, stage, trials and the evidence behind it.